Full year 2024 for the period 1 January - 31 December (Q4’2024 results in brackets):

• Net revenue was KDKK 2.486 (-870)
• Operating result was KDKK -19.053 (-8.667)
• Net result was KDKK -14.670 (-7.216)
• Cash at bank end of the period was KDKK 12.373 (12.373)
• Earnings per share* was KDKK -0,85 (-0,41)
• Solidity** was 52% (52%)

*Earnings per share (DKK per share): Operating result divided by the average number of shares during the period. The total number of shares as of 31 December 2024 amounted to 17.425.094 shares, the average number of shares during the full year was 17.248.469. **Solidity: Total equity divided by total capital and liability.

The annual report is presented for approval at the Annual General Meeting, 28 March 2025. The Board and the CEO have proposed that no dividend is paid out for the fiscal year, 1 January 2024 - 31 December 2024.

Highlights during the full year 2024

Q1-2024

• Successful TO2 warrant exercise - 94.7 percent of all outstanding TO2 Warrants were exercised for subscription of shares. Cessatech received approximately DKK 17.1 million in gross proceeds

Q2-2024

• The Paediatric Study 0202 was initiated with dosing of the first patient
• Data presented at a meeting in Rome; simulated pain reduction in NRS in children using CT001 was -87%, compared to -52%, -32% and +10% for sufentanil, ketamine and placebo respectively

Q3-2024

• The Loan Facility Agreement with a group of investors was increased from DKK 5 million to DKK 10 million and the maturity extended until April 2026

Q4-2024

• Recruitment reached the halfway point for patient recruitment with 75 included patients in the Paediatric Study 0202

For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com

About Cessatech
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercializing evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, easy administration, a fast-acting therapeutic effect, and being medically approved for children. CT001 is at its pivotal stage of clinical development, and CT002 is at the early development phase.